{"id":"W2949515538","doi":"10.1016/j.ejca.2019.05.008","title":"Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial","year":2019,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":217,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Alberta","funders":"Foundation Medicine; Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Ipilimumab; Nivolumab; Medicine; Oncology; Internal medicine; Lung cancer; Chemotherapy; Open label; Cancer; Immunotherapy; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001107222,0.001144214,0.002310813,0.0002698854,0.0002476032,0.001187446,0.0007347717,0.001230354,0.003354698],"category_scores_gemma":[0.001432857,0.000364547,0.002285016,0.0002348289,0.0007230558,0.000854123,0.0003453508,0.002743575,0.0007196235],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001051879,"about_ca_system_score_gemma":0.0007053413,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001382446,"about_ca_topic_score_gemma":0.003441687,"domain_scores_codex":[0.9995982,0.0002100084,0.00001539391,0.00008355156,0.00002689376,0.0000659567],"domain_scores_gemma":[0.9993805,0.0002166182,0.0001353759,0.000050542,0.00002848714,0.0001885432],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9578387,0.002989799,0.001464377,0.0009546818,0.002508919,0.0000413114,0.0000567756,0.001431245,0.002550737,0.000156247,0.001472894,0.02853434],"study_design_scores_gemma":[0.9068291,0.07797623,0.008305425,0.0001289144,0.002248425,0.0001025436,0.00007238908,0.001639129,0.0008435403,0.000477688,0.001340642,0.00003608637],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9894236,0.006106221,0.0002981947,0.0005564379,0.0004113278,0.0004792327,0.0009689056,0.00008055286,0.001675607],"genre_scores_gemma":[0.9930386,0.001827733,0.0004728615,0.0007219377,0.0001808877,0.0004341078,0.001174818,0.00002281409,0.002126172],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003354698,"threshold_uncertainty_score":0.0112226,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02583722178502796,"score_gpt":0.3212381747489892,"score_spread":0.2954009529639613,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}